JC03 Rec'd PCT/PTO 22 JUN 2005

FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE (REV. 2-2005)

## TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

RLL-283US

CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/540062

INTERNATIONAL APPLICATION NO. PCT/IB2002/005591

INTERNATIONAL FILING DATE 23 December 2002

PRIORITY DATE CLAIMED

ITLE OF INVENTION FLAVAXATE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS									
PPLI	ICAN'	T(S) FOR DO/EO/US							
		A et al.							
- alic	ant h	erewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:							
•	_								
1.	×	This is a <b>FIRST</b> submission of items concerning a submission under 35 U.S.C. 371.							
2.		This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.							
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.							
4.		The US has been elected (Article 31).							
5.	$\boxtimes$	A copy of the International Application as filed (35 U.S.C. 371 (c)(2))							
		a.  is attached hereto (required only if not communicated by the International Bureau).							
		b. 🖾 has been communicated by the International Bureau.							
_	_	c. is not required, as the application was filed in the United States Receiving Office (RO/US).							
6.	☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).								
		a. I is attached hereto.							
	~~21	b. has been previously submitted under 35 U.S.C. 154(d)(4).							
7.									
		a. are attached hereto (required only if not communicated by the International Bureau).							
		b. have been communicated by the International Bureau.							
		c. have not been made; however, the time limit for making such amendments has NOT expired.							
_	_	d. Make not been made and will not be made.							
8.	<b>⊠</b>	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9.	⊠ □	An earth or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).							
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).							
11.	×	A copy of the International Preliminary Examination Report (PCT/IPEA/409).							
12.	$\boxtimes$	A copy of the International Search Report (PCT/ISA/210).							
Ite	ms 1	3 to 23 below concern document(s) or information included:							
13.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
15.		A FIRST preliminary amendment.							
16.		A SECOND or SUBSEQUENT preliminary amendment.							
17.		A substitute specification.							
18.		A power of attorney and/or change of address letter.							
19.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.							
20.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).							
21.		A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).							
22. 🔊	_	Express Mail Label No. EV 674776977 US							
23.	<b>×</b>	Other items or information:							
		Return Postcard Certificate of Express Mailing							

JC20 Rec'd RCT/PTO 2 2 P10 1 No 760 5-2005)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO.						ATTORNEY'S DOCKET NUMBER				
10/540062 PCT/IB2002/005591					RLL-283US					
	g fees are submitte	CALCULATIONS	PTO USE							
	ational fee	\$300	\$ \$300.00							
If International pr satisfy provisions	ation fee eliminary examina of PCT Article 33 os	\$ \$200.00								
Search fee (37 C the USPTO as an International Sea All other situation	fee	\$ \$400.00 \$ \$900.00								
		3 3900.00								
sequence lis \$250 for each	e for specification sting or computer p th additional 50 sh									
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole			RATE					
25 - 100 =	0 /50 =		0			\$ \$0.00				
	0.00 for furnishing oriority date (37 C	\$								
CLAIMS	CLAIMS NUMBER FILED NUMBER EXTRA RATE									
Total claims	18	0	x	\$50.00	\$ \$0.00					
Independent clair	ms 4	- 3=	1	x	\$200.00	\$ \$200.00				
MULTIPLE DEPENDENT CLAIMS (if applicable)   → \$						\$ \$360.00				
		TOT	AL OF ABOVE CA	ALC	ULATIONS =	\$ \$1,460.00				
☐ Applicant cla reduced by	aims small entity s	\$ \$0.00								
,	<u>-</u> -	\$ \$1,460.00	· · · · · · · · · · · · · · · · · · ·							
	f \$130.00 for furnised priority date (3		plish translation later th	an 30	) months from	\$ \$0.00				
	, , , , , , , , , , , , , , , , , , , ,			IATI	ONAL FEE =	\$ \$1,460.00				
Fee for recording accompanied by	the enclosed assi an appropriate cov	gnment (37 ( ør sheet (37	CFR 1.21(h)). The ass CFR 3.28, 3.31). <b>\$40</b>	ignm per p	ent must be property +	\$ \$0.00				
			TOTAL FEE	SE	NCLOSED =	\$ \$1,460.00	·			
		Amount to be	s							
						Amount to be	s			
a. 🔲 A check	in the amount of \$	<b>.</b>	to cover the a	bove	fees is enclosed		1			
-· <b>-</b>	charge my Deposit			n the	amount of	\$1,460.00 to cove	r the above fees.			
A duplicate copy of this sheet is enclosed.  c.   The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Denosit Account No. 20, 0013 Advantage only of this sheet is enclosed.										
to Deposit Account No A duplicate copy of this sheet is enclosed.  d. □ Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card										
information should not be included on this form. Provide credit card information and authorization on PTO-2038.  NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.										
	d granted to rest	VED Ilan	,							
Jayadeep R. Des		ony, reac								
Reg. No. 34,507	•	. Hare								
Customer No. 20	0815									
					44,739					
		ON NUMBER								

10/540062 RLL-283US

## JC20 Rec'd PCT/PTO 22 JUN 2005 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

MEHTA et al.

International Application No.

PCT/IB2002/005591

International Filing Date:

23 December 2002

Title:

FLAVAXATE DERIVATIVES AS MUSCARINIC

RECEPTOR ANTAGONISTS

## **CERTIFICATE OF EXPRESS MAILING**

I hereby certify that the following correspondence:

- Transmittal Letter to the DO/EO/US Concerning a Submission Under 371
- Unexecuted Declaration And Power of Attorney for Patent Application
- International Search Report
- International Preliminary Examination Report
- Return Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on June 22, 2005.

Susan Dolci
Name of Person Mailing Correspondence

Signature

EV 674776977 US

"Express Mail" Mailing Label Number